|
|
|
Brentuximab Vedotin (13)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Systemic anaplastic large cell lymphoma; first-line; combination with cyclophosphamide, doxorubicin and prednisone
|
n.d.
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (8)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Hodgkin's lymphoma, CD30+, pre-treated
|
n.d.
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (9)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Systemic anaplastic large cell lymphoma (sALCL) , relapsed, refractory
|
n.d.
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (10)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Hodgkin's lymphoma, CD30+, increased risk of recurrence or progression after transplantation
|
n.d.
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (11)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Cutaneous T-cell lymphoma, CD30+, pre-treated
|
n.d.
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (12)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Hodgkin's lymphoma, CD30+, first-line, stage III + IV, in combination with doxorubicin, vinblastine and dacarbazine
|
n.d.
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (7)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Hodgkin-Lymphoma (CD30+, first-line, stadium III, in combination with Doxorubicin, Vinblastin and Dacarbazin)
|
n.d.
|
discontinued
Orphan
|
|
|
|
Brentuximab Vedotin (6)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Systemic anaplastic large cell lymphoma; sALCL; first-line; combination with cyclophosphamide, doxorubicin and prednisone
|
125–127
|
100%
Hint for
minor additional benefit
Orphan
|
|
|
|
Brentuximab Vedotin (5)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Systemic anaplastic large cell lymphoma; first-line; combination with cyclophosphamide, doxorubicin and prednisone
|
0
125–127
|
100%
Hint for
minor additional benefit
Orphan
repealed
|
|
|
|
Brentuximab Vedotin (4)
|
Adcetris®
|
Takeda GmbH & Co. KG
|
Oncological diseases
|
Hodgkin lymphoma (HL), CD30+, first-line
|
220–380
|
100%
non-quantifiable additional benefit
Orphan
|
|
|
|
Brentuximab Vedotin (3)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Cutaneous T-cell lymphoma, CD30+
|
40–130
|
100%
minor additional benefit
Orphan
|
|
|
|
Brentuximab Vedotin (2)
|
Adcetris®
|
Takeda GmbH
|
Oncological diseases
|
Hodgkin lymphoma (HL), CD30+, increased risk of recurrence or progression after transplantation
|
40–60
|
100%
non-quantifiable additional benefit
Orphan
|
|
|
|
Brentuximab Vedotin (1)
|
Adcetris®
|
Takeda Pharma Vertrieb GmbH & Co. KG
|
Oncological diseases
|
Hodgkin lymphoma (HL), CD30+; Systemic anaplastic large cell lymphoma
|
75–420
|
100%
non-quantifiable additional benefit
Orphan
|
